Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles

Tools

Dufès, Christine and Muller, Jean-Marc and Couet, William and Olivier, Jean-Christophe and Uchegbu, I.F. and Schätzlein, Andreas G. (2004) Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles. Pharmaceutical Research, 21 (1). pp. 101-7. ISSN 0724-8741 (https://doi.org/10.1023/B:PHAM.0000012156.65125.01)

[thumbnail of Dufes 2004]
Preview
 PDF. Filename: Dufes_et_al2004Doxvesicles.pdf
Final Published Version
Download (222kB)| Preview

Abstract

The study reports the initial biological evaluation of targeted polymeric glycol chitosan vesicles as carrier systems for doxorubicin (Dox). Transferrin (Tf) was covalently bound to the Dox-loaded palmitoylated glycol chitosan (GCP) vesicles using dimethylsuberimidate (DMSI). For comparison, glucose targeted niosomes were prepared using N-palmitoyl glucosamine. Biological properties were studied using confocal microscopy, flow cytometry, and cytotoxicity assays as well as a mouse xenograft model. Tf vesicles were taken up rapidly with a plateau after 1-2 h and Dox reached the nucleus after 60-90 min. Uptake was not increased with the use of glucose ligands, but higher uptake and increased cytotoxicity were observed for Tf targeted as compared to GCP Dox alone. In the drug-resistant A2780AD cells and in A431 cells, the relative increase in activity was significantly higher for the Tf-GCP vesicles than would have been expected from the uptake studies. All vesicle formulations had a superior in vivo safety profile compared to the free drug. The in vitro advantage of targeted Tf vesicles did not translate into a therapeutic advantage in vivo. All vesicles reduced tumor size on day 2 but were overall less active than the free drug.

ORCID iDs

Dufès, Christine ORCID logoORCID: https://orcid.org/0000-0002-7963-6364, Muller, Jean-Marc, Couet, William, Olivier, Jean-Christophe, Uchegbu, I.F. and Schätzlein, Andreas G.;
CORE (COnnecting REpositories)